Clinical trials: Duration of Response
Plaque Psoriasis
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Stable Plaque Psoriasis.
- Trial name
- NCT00733954
- Testing
- clobetasol propionate spray, clobetasol propionate ointment
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Galderma R&D
Effects of Unilateral Quadriceps Static Stretching on Muscle Strength and Jumping Performance
Time Course of Responses to Unilateral Quadriceps Static Stretching
This study investigated whether unilateral static stretching of the quadriceps muscles produces immediate and short-term changes in muscle strength and jumping performance in both the stretched and unstretched legs.
- Trial name
- NCT07860944
- Testing
- Unilateral Quadriceps Static Stretching
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- İbrahim Dündar
Stress
Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training
We are looking at the effects of Stress Management and Relaxation Response training on stress hormones (like adrenalin and cortisol), immune function and physiology (heart rate, breathing rate, muscle tension).
- Trial name
- NCT00636129
- Testing
- Relaxation Response + Stress Management Curriculum
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation, Out of Hospital Cardiac Arrest
RESTORE-ZG: Return of Effective Spontaneous Circulation Resuscitation Evaluation Canton of Zug
This study looked at cardiac arrest that happens outside a hospital. Cardiac arrest means the heart suddenly stops pumping blood. When this happens, a person collapses and needs help right away.
- Conditions
- Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation, Out of Hospital Cardiac Arrest, Out of Hospital Setting, Defibrillation
- Trial name
- RESTORE-ZG (NCT07750119)
- Testing
- Prehospital resuscitation care
- Where
- Switzerland
- Volunteers
- 240 people
- Sponsor
- Felix Brinkmann
Spinal Cord Injuries, Incomplete Spinal Cord Injury
A Novel System for Quasi Real-Time Tracking of Neuromuscular Responses During NMES
Neuromuscular electrical stimulation (NMES) remains as one of the effective rehabilitation modalities for addressing recovery of neuromuscular function after a spinal cord injury (SCI).
- Trial name
- NCT05243576
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Toxicity, Non-small Cell Lung Cancer
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01192243
- Testing
- Gefitinib, Pemetrexed, Cisplatin or carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Gastric Cancer
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
The purpose of this study is to evaluate the efficacy and overall survival of the regimen of XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.
- Trial name
- NCT00568529
- Testing
- Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Parkinson's Disease
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time phenomena and advanced Parkinson's disease…
- Trial name
- NCT00456794
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Kyowa Kirin, Inc.
CHRONIC MYELOGENOUS LEUKEMIA
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
The primary goal of this study was to determine the rate of confirmed best cumulative complete molecular response (CMR) within the first year of study therapy with imatinib or nilotinib.
- Trial name
- NCT00760877
- Testing
- Nilotinib, Imatinib
- Where
- 30 sites in Argentina, Australia and 4 more
- Volunteers
- 207 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400 mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in patients with genotype 2 or 3 chronic hepatitis…
- Trial name
- NCT00532701
- Testing
- Peg-IFN + WB RBV for 16 weeks, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks
- Where
- 9 sites in Taiwan
- Volunteers
- 880 people
- Sponsor
- National Taiwan University Hospital
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199407
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Kyowa Kirin, Inc.
Yellow Fever Vaccine
Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military
Yellow fever is an acute viral disease transmitted by mosquitoes in South America, Central America and Africa. It is more prevalente in males gender and the age above 15 years due to the greater exposure in the wild endemic area…
- Trial name
- NCT03338231
- Where
- Brazil
- Volunteers
- 374 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Fibromyalgia
Fibromyalgia of Less Than One Year Duration. Study of Pregabalin
The purpose of the study is to evaluate whether pregabalin is effective in treating subjects who have had fibromyalgia for less than one year. Pregabalin has been approved by the FDA for treatment of fibromyalgia.
- Trial name
- NCT01397006
- Testing
- Pregabalin
- Where
- United States
- Sponsor
- Newton-Wellesley Hospital
Depression, Major Depressive Disorder
Effect of SSRIs on Response to Psilocybin Therapy
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting.
- Conditions
- Depression, Major Depressive Disorder, Mild Depression, Moderate Depression
- Trial name
- NCT05594667
- Testing
- Psilocybin
- Where
- Canada
- Sponsor
- Cybin Therapeutics Inc.
Asthma
mRNA Expression as a Biomarker of Omalizumab Response
Objectives: 1. Determine if mRNA expression could be use as a biomarker to predict and monitor the response to omalizumab in patients with difficult control asthma 2.
- Trial name
- NCT01584687
- Testing
- Omalizumab
- Volunteers
- 6 people
- Sponsor
- Instituto de Investigação em Imunologia
Chronic Hepatitis C Infection
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
- Trial name
- NCT01225380
- Testing
- GS-9190, GS-9256, Pegasys®
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 324 people
- Sponsor
- Gilead Sciences
Shock, Septic
Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock
The role of albumin in sepsis has been controversial for decades. Although hypoalbuminemia has been associated with worse outcomes in sepsis, definitive evidence does not exist that replacing albumin in these patients improves…
- Trial name
- NCT02716597
- Testing
- 25% Albumin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Alexander Flannery, 859-323-4011
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
This 6-arm study will assess the efficacy and safety of RO5024048 (R7128) in combination with the approved doses of Pegasys (180micrograms sc weekly) + Copegus (1000/1200mg po daily) (SOC), versus SOC in treatment-naive patients…
- Trial name
- NCT00869661
- Testing
- Copegus, Pegasys, RO5024048
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 413 people
- Sponsor
- Hoffmann-La Roche
Wounds
Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications
The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and…
- Trial name
- NCT01378728
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
Hepatitis B, Hepatitis A
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
To evaluate the persistence of immune response 5 years and 6 years after the first vaccine dose.
- Trial name
- NCT00197171
- Testing
- Combined Hepatitis A and B vaccine
- Where
- 2 sites in Australia
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline